Navigation Links
Ameritox® Continues to Advance Industry Leadership

BALTIMORE, Feb. 4, 2011 /PRNewswire/ -- Ameritox®, the nation's leader in pain medication monitoring, made significant strides to advance its industry leadership position by strengthening the company's commitment to physicians and patients in the past twelve months.  Through significant investments in clinical research and an expansion of its laboratory capabilities, Ameritox has reached several milestones – including the analysis of nearly 2.5 million patient samples with its proprietary RxGuardian(SM) offering to healthcare partners.

"We're proud to have reached these milestones through the work of dedicated staff in our Greensboro (NC) and Midland (TX) labs and Baltimore (MD) headquarters, expanding our science-based technology, enhancing service to our physician partners and investing in meeting our customers' needs," said Ancelmo Lopes, CEO of Ameritox.

Clinical and Research Highlights:  Ameritox, long-known for its service and partnership with healthcare providers, leads the industry with an innovative research program to re-define the field of pain medication monitoring.  The Baltimore-based company is the largest laboratory focused exclusively on supporting clinicians who treat patients with chronic pain.  Significant research and clinical advances have expanded the tools Ameritox offers to its physician partners, and the corporation's research program continues to lead the industry.

By adding to the body of knowledge regarding managing patients on chronic opioid therapy, Ameritox continues to assist physicians in making better treatment decisions. In the past two years, nine key studies have been accepted for or presented at national clinical meetings.  Four studies have also been published in respected peer-reviewed journals.

In 2010, Ameritox presented three studies at the American Academy of Pain Management meeting (AAPM).  A landmark study published in the Journal of Opioid Management demonstrated how the proprietary Ameritox Rx Guardian(SM) algorithm, when applied to urine drug levels of OxyContin® C-II (oxycodone HCL controlled-release) tablets, differentiated among three different daily doses of the drug, thus surpassing traditional urine testing. A second study, published in January in The Journal of Clinical Pharmacy and Therapeutics, described Rx Guardian's efficacy in discriminating between  all three daily doses of hydrocodone tested (20, 60, 120 mg).  An important health economics study also published in January in the American Journal of Managed Care, "Chronic Opioid Adherence and Healthcare Costs in a Managed Care Population," linked opioid prescription non-adherence with significantly elevated health care costs.  These findings have particular relevance in today's debate on healthcare costs.

Laboratory NewsAmeritox opened a second state-of-the-art laboratory facility in Greensboro, North Carolina in 2010, significantly expanding its ability to serve physicians and their patients nationwide. The administrative and lab facilities have exceeded expectations of productivity and now test hundreds of thousands of patient samples annually. With nearly 130 skilled, full-time employees performing leading-edge pain medication monitoring, the Greensboro facility has made a major impact on the company's growth.

Ameritox's Midland, Texas, facility welcomed Congressman Mike Conaway (R-TX) of the 11th District for a tour of the laboratory. Currently, Ameritox employs nearly 230 people in the greater Midland area at both its laboratory facility and at its new administrative facility in downtown Midland.  

"We're honored to be a partner in the communities where our facilities are located," said Lopes of Ameritox.  "Our technology is dependent on skilled workers and we're fortunate to be located in two hubs where skilled workers abound."

Marshfield PartnershipAmeritox secured licensing rights from Marshfield Clinic to continue developing a new technology to assist in determining the likelihood of patient adherence. Ameritox will further develop this technology for commercialization and support additional research and development, greatly expanding the scope and usability of pain medication monitoring among its physician partners.

Team Ameritox:Adding to considerable bench strength within the company, the Ameritox team has grown significantly to enhance support for the company's physician partners across the nation.

As a further benefit to both the physician service and  leading Medical Science Liaison team for which it is known, Ameritox has appointed Kathryn S. Bronstein, PhD, RN, as Director of Medical Science and Health Outcomes, and expanded its Medical Science Liaison team with the additions of David E. Chapman, PhD; Monica A. Fay, PharmD., MBA; Lisa M. Burke, PhD, MBA, RN; and Barry Cohen, PhD as Assistant Directors of Medical Science and Health Outcomes Research.  Kendra L. Davies, B.S., PharmD, also joined as Associate Director, Medical Affairs, rounding out a team focused on maintaining the highest level of clinical and research rigor in the industry.  

The company has also formed a new Government Programs department to expand support to public health care providers who manage patients on chronic opioid therapy.

About Ameritox Ameritox is the nation's leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provides physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers Rx Guardian(SM), the most thorough and personalized lab service available and the only pain medication testing program with a proprietary methodology to help physicians assess whether patients are taking their pain medication as directed. Medication monitoring helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, MD with laboratory facilities in Midland, TX and Greensboro, NC.

© 2011, Ameritox, Ltd. All rights reserved. AMERITOX, the AMERITOX logos, PAIN MEDICATION MONITORING SOLUTIONS, AMERITOX MEDICATION MONITORING SOLUTIONS, Rx GUARDIAN AUTOREMINDER, Rx GUARDIAN and PROTECT YOUR PATIENTS, PROTECT YOUR PRACTICE, are trademarks of Ameritox. All other trademarks are the claimed trademarks of others.For more information, contact: Michele Hart-Henry

SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adult Smoking Rate Continues Downward Trend
2. Gilbert Hospital Continues Cutting Edge Treatments
3. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
4. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
5. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
6. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
7. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
8. Medarex Announces Ipilimumab Program Continues to Move Forward
9. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
10. Replidyne Discontinues Phase III Trial
11. AlphaVax Continues to Expand the Use of Its Vaccine Platform
Post Your Comments:
(Date:10/12/2015)... YORK , Oct. 12, 2015 About ... Epilepsy refers to a spectrum of brain disorders manifested ... is caused by factors ranging from brain malformations and ... When the underlying cause of the disease is unidentified, ... is known as idiopathic epilepsy. An imbalance between the ...
(Date:10/12/2015)... 2015 --> --> ... by Product (Hand-held, Table-top, Desktop), Technology (Volume Measurement, Flow Measurement, ... - Global Forecast to 2020", published by MarketsandMarkets, the Spirometer ... at a CAGR of 9.8% from 2015 to 2020. ... igures spread th rough 187 P ages and ...
(Date:10/12/2015)... IRVINE, Calif. , Oct. 12, 2015  Edwards Lifesciences ... science of heart valves and hemodynamic monitoring, plans to announce ... after the market closes on Monday, October 26, 2015, and ... day to discuss those results. . A ... mobile devices by downloading Edwards, IR App for iPhone ...
Breaking Medicine Technology:
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... ... treatment possible for children with autism, PediaPlex , a Southlake, Texas, child ... of ABA Therapy and educating military families about their options for ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... and eco-friendly home furnishings and décor, today announced it closed on a $20.5 ... The funds will be used to support the Company’s continued rapid growth and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
(Date:10/13/2015)... ... , ... Curly Hair Solutions® is thrilled to be a ... featuring the newest products and services to hit the market for women. With ... to unveil their recent partnership with Trade Secrets, a leading Canadian beauty retailer. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... presented results from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test ... World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. , ...
Breaking Medicine News(10 mins):